ELENCO PUBBLICAZIONI SCIENTIFICHE

1. Lovato G, Ciriolo L, Perrucci M, Federici L, Ippoliti R, Iacobelli S, **Capone E**, Locatelli M, Sala G. HPLC-DAD validated method for DM4 and its metabolite S-Me-DM4 quantification in biological matrix for clinical and pharmaceutical applications. J Pharm Biomed Anal. 2023 Oct 25;235:115642. doi: 10.1016/j.jpba.2023.115642. Epub 2023 Aug 12. PMID: 37586307. [IF: 3.1]

2. Keinänen O, Sarrett SM, Delaney S, Rodriguez C, Dayts EJ, **Capone E**, Sauniere F, Ippoliti R, Sala G, Iacobelli S, Zeglis BM. Visualizing Galectin-3 Binding Protein Expression with ImmunoPET. Mol Pharm. 2023 Jun 5;20(6):3241-3248. doi: 10.1021/acs.molpharmaceut.3c00241. Epub 2023 May 16. PMID: 37191353; PMCID: PMC10245371. [IF: 3.2]

3. Capone E, Perrotti V, Cela I, Lattanzio R, Togni L, Rubini C, Caponio VCA, Lo Muzio L, Colasante M, Giansanti F, Ippoliti R, Iacobelli S, Wick MJ, Spardy Burr N, Sala G. Anti-LGALS3BP antibody-drug conjugate treatment induces durable and potent antitumor response in a preclinical model of adenoid cystic carcinoma. Oral Oncol. 2024 Jan;148:106635. doi: 10.1016/j.oraloncology.2023.106635. Epub 2023 Nov 21. PMID: 37988837. [IF: 3.9]

4. Cela I, Caponio VCA, **Capone E**, Pinti M, Mascitti M, Togni L, Lo Muzio L, Rubini C, De Laurenzi V, Lattanzio R, Perrotti V, Sala G. LGALS3BP is a potential target of antibody-drug conjugates in oral squamous cell carcinoma. Oral Dis. 2024 May;30(4):2039-2050. doi: 10.1111/odi.14719. Epub 2023 Aug 31. PMID: 37649401. [IF: 2.9]

5. Cela I, **Capone E**, Trevisi G, Sala G. Extracellular vesicles in glioblastoma: Biomarkers and therapeutic tools. Semin Cancer Biol. 2024 Jun;101:25-43. doi: 10.1016/j.semcancer.2024.04.003. Epub 2024 May 14. PMID: 38754752. [IF: 15.7]

6. Bibbò S[#], **Capone E**[#], Lovato G, Ponziani S, Lamolinara A, Iezzi M, Lattanzio R, Mazzocco K, Morini M, Giansanti F, De Laurenzi V, Whitfield J, Iacobelli S, Ippoliti R, Beaulieu ME, Soucek L, Sala A, Sala G. EV20/Omomyc: A novel dual MYC/HER3 targeting immunoconjugate. J Control Release. 2024 Oct;374:171-180. doi: 10.1016/j.jconrel.2024.08.009. Epub 2024 Aug 14. PMID: 39128771. [IF: 11.5]

7. Cela I, **Capone E**, Pece A, Lovato G, Simeone P, Colasante M, Lamolinara A, Piro A, Iezzi M, Lanuti P, De Laurenzi V, Ippoliti R, Iacobelli S, Sala G. LGALS3BP antibody-drug conjugate enhances tumor-infiltrating lymphocytes and synergizes with immunotherapy to restrain neuroblastoma growth. J Transl Med. 2025 Apr 11;23(1):431. doi: 10.1186/s12967-025-06434-1. PMID: 40217513; PMCID: PMC11992825. [IF: 7.5]

8. Tisci G, Rajsiglova L, Bibbo S, Zicchedu G, Ricciardi E, Falvo E, De Laurenzi V, Sala G, **Capone E,** Colotti G, Arcovito A, Giacon N, Makovický P, Sushytskyi L, Lukac P, Vannucci L, Giacomini P, Ceci P. A first-in-class non-cytotoxic nanocarrier based on a recombinant human ferritin boosts targeted therapy, chemotherapy and immunotherapy. Int J Biol Macromol. 2025 May;309(Pt 1):142843. doi: 10.1016/j.ijbiomac.2025.142843. Epub 2025 Apr 3. PMID: 40187454. [IF: 8.5]

9. Lovato G, Perrucci M, Cela I, Lamolinara A, Mercatelli A, De Laurenzi V, **Capone E**, Locatelli M, Sala G. Evaluation of Antibody-Drug Conjugate Performances Using a Novel HPLC-DAD Method for Tumor-Specific Detection of DM4 and *S*-Methyl-DM4. ACS Omega. 2025 Oct 15;10(42):50382-50393. doi: 10.1021/acsomega.5c07693. PMID: 41179189; PMCID: PMC12572975. [IF: 4.3]

10. Pece A, Lovato G, Cela I, Mercatelli A, Ferro B, Nikkola J, Pagotto S, Grottola T, De Laurenzi V, Cicchetti R, Marchetti A, Schips L, Lattanzio R, Iacobelli S**, Capone E**, Black P, Daugaard M, Marchioni M, Sala G. Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker. Mol Oncol. 2025 Oct 5. doi: 10.1002/1878- 0261.70140. Epub ahead of print. PMID: 41046347. [IF: 4.5]

La Sottoscritta Emily Capone consapevole che chiunque rilascia dichiarazioni mendaci è punito ai sensi del codice penale e delle leggi speciali in materia, ai sensi e per gli effetti degli art. 46 e 47 D.P.R. n. 445/2000.

Luogo e data
CHIETI 17 Aprile 2026

Firma del dichiarante



Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 e del GDPR (Regolamento UE 2016/679).